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The type II fatty-acid biosynthesis pathway of bacteria provides enormous
potential for antibacterial drug development owing to the structural differences
between this and the type I fatty-acid biosynthesis system found in mammals.
-Ketoacyl-ACP reductase (FabG) is responsible for the reduction of the
-ketoacyl group linked to acyl carrier protein (ACP), and is essential for the
formation of fatty acids and bacterial survival. Here, the cloning, expression,
purification, crystallization and diffraction of FabG from Yersinia pestis
(ypFabG), the highly virulent causative agent of plague, are reported.
Recombinant FabG was expressed, purified to homogeneity and crystallized
via the hanging-drop vapour-diffusion technique. Diffraction data were
collected at the Australian Synchrotron to 2.30 A˚ resolution. The crystal
displayed P212121 symmetry, with unit-cell parameters a = 68.22, b = 98.68,
c = 169.84 A˚, and four ypFabG molecules in the asymmetric unit.
1. Introduction
The fatty-acid biosynthesis pathway of bacteria provides a number of
extremely promising antibacterial drug targets. Most bacteria utilize
the type II fatty-acid biosynthesis (FASII) system, in which discrete
dissociated enzymes sequentially catalyse the creation of saturated
and unsaturated fatty acids of varying lengths from the condensation
of malonyl-CoA and acetyl-CoA primers. Such fatty acids form
essential components of lipoproteins, phospholipids and lipopoly-
saccharides (Parsons & Rock, 2013). In contrast, the type I fatty-acid
system (FASI) of mammalian cells is a multifunction protein complex
comprised of a homodimer of two 270 kDa polypeptides encoded by
a single gene, with the various domains of the complex catalysing the
acyltransferase, condensation, reduction and dehydration reactions
of the pathway (Asturias et al., 2005). Whilst the individual reactions
in both FASI and FASII are similar, the structural differences
between the FASI complex and the dissociated enzymes of the FASII
system provide the potential to target an area essential to bacterial
survival with minimal adverse effects to the host (Leibundgut et al.,
2008; White et al., 2005).
FabG catalyses the reduction of the ACP (acyl carrier protein)-
bound -ketoacyl group to a -hydroxyacyl group and is necessary
for the formation of both saturated and unsaturated fatty acids. It is
expressed in most bacteria as a single isozyme of approximately 25–
26 kDa, forming either a homodimer or homotetramer in solution.
The overall structure including the Ser, Tyr and Lys catalytic triad of
the active site (Dutta et al., 2012; Price et al., 2001) appears to be well
conserved in both Gram-negative and Gram-positive bacteria, with
an r.m.s.d. of 1.5 A˚ between Staphylococcus aureus FabG (PDB entry
3osu; Center for Structural Genomics of Infectious Diseases,
unpublished work) and Escherichia coli FabG (PDB entry 1i01; Price
et al., 2001) (calculated using DaliLite; Holm & Park, 2000). FabG
also appears to be essential for bacterial survival (Lai & Cronan,
2004; Subramanian et al., 2011; Tang et al., 2006). One notable
exception to this is bacteria of theMycobacterium genus, in which five
putative isozymes have been identified; however, the roles of these
isozymes have yet to be characterized (Gurvitz, 2009; Parish et al.,
2007).
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This paper describes the cloning, expression, purification, crystal-
lization and preliminary X-ray diffraction analysis of FabG from
Yersinia pestis, the causative agent of bubonic, pneumonic and
septicaemic plague. If left untreated Y. pestis infections are usually
fatal, resulting in death in as little as 24 h after exposure (Bertherat et
al., 2011). Additionally, bubonic and septicaemic plague can advance
to pneumonic plague (infection in the lungs), a highly contagious
manifestation in which human-to-human transmission can occur
through respiratory droplets (Bertherat et al., 2011; Zhou & Yang,
2009). In recent years, multidrug-resistant isolates of Y. pestis have
been observed (Galimand et al., 2006), indicating a need to develop
new antimicrobials to treat infection.
2. Experimental methods
2.1. Cloning
The gene encoding ypFabG (accession No. NP_669075.1) was
amplified from genomic DNA by polymerase chain reaction (PCR)
using HotStarTaq PCR Master Mix (Qiagen). The PCR product was
inserted into the expression vector pMCSG21 via ligation-indepen-
dent cloning as described previously (Eschenfeldt et al., 2009), with
the following modifications: T4 treatment was conducted using 80 ng
of PCR product and 1.5 ml (4 U) of T4 polymerase. T4-treated
products were annealed using a 3:1 ratio of insert to vector before
being transformed into chemically competent E. coli TOP10 cells
(Invitrogen). The final construct encoded full-length ypFabG fused
to an N-terminal hexahistidine tag with a Tobacco etch virus (TEV)
protease cleavage site for tag removal.
2.2. Expression and purification
Protein expression and purification were performed similarly to
that described by Forwood et al. (2007). Plasmid containing recom-
binant ypFabG was transformed into E. coli BL21 (DE3) pLysS
competent cells. A single colony was used to inoculate a 5 ml Luria–
Bertani (LB) starter culture supplemented with spectinomycin
(100 mg ml1) and chloramphenicol (34 mg ml1), and was then used
to inoculate auto-induction medium (Studier, 2005) containing
spectinomycin (100 mg ml1) and chloramphenicol (34 mg ml1),
which was incubated at 310 K until an OD600 of 6–10 was reached.
Cells were harvested by centrifugation at 7459g at 277 K before being
resuspended in buffer A (50 mM phosphate buffer pH 8.0, 300 mM
NaCl, 20 mM imidazole) to a final volume of 35 ml and frozen at
253 K. Cell pellets were thawed and incubated with 1 ml 20 mg ml1
lysozyme and 10 ml 50 mg ml1 DNAse on ice for 30 min. The cell
lysate was cleared via centrifugation and the recombinant protein was
purified using affinity chromatography (HisTrap HP, GE Healthcare)
equilibrated with buffer A. Protein was eluted using an increasing
concentration of buffer B (50 mM phosphate buffer pH 8.0, 300 mM
NaCl, 500 mM imidazole). Following elution, pooled fractions (14 ml)
were incubated with 200 ml TEV protease (5 mg ml1) for 14 h at
277 K (additional residues following tag removal: SNA–) before
being further purified by size-exclusion chromatography (HiLoad
26/60 S200 column, GE Healthcare). Fractions containing ypFabG
were eluted in buffer C (50 mM Tris pH 8.0, 125 mM NaCl) and
concentrated to 70 mg ml1 using an Amicon ultracentrifugal device
(Millipore) with a 10 kDa molecular-weight cutoff. The concentrated
protein was assessed by SDS–PAGE to be >95% pure, and was
aliquoted and stored at 253 K.
2.3. Crystallization
Screening for initial crystallization conditions was conducted using
the following commercially available screens: Crystal Screen, Crystal
Screen 2, PEG/Ion and PEG/Ion 2 (Hampton Research). Screening
was performed in VDX 48-well plates (Hampton Research) via the
hanging-drop vapour-diffusion technique, using 1.5 ml recombinant
ypFabG solution combined with 1.5 ml reservoir solution suspended
over 300 ml reservoir solution and incubated at 296 K. Further opti-
mization was conducted by varying salt and additive concentrations,
and varying the concentration of protein using neat and 1:2 dilutions
of recombinant ypFabG solution (diluted in buffer C). Large
diffraction-quality crystals were obtained in 300 mM ammonium
phosphate monobasic, 30%(w/v) glycerol, using a protein concen-
tration of 35 mg ml1.
2.4. Data collection and molecular replacement
ypFabG crystals were flash-cooled in liquid nitrogen at 100 K on
day 12. Diffraction data were collected at the Australian Synchrotron
on the MX2 microcrystallography beamline. A total of 200 of data
with 0.5 oscillations were collected at a wavelength of 0.9537 A˚ and a
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Figure 1
Recombinant ypFabG was purified using (a) affinity chromatography (HisTrap HP,
GE Healthcare) and (b) size-exclusion chromatography. Protein expression and
purity were assessed by SDS–PAGE (not shown).
crystal-to-detector distance of 240 mm. Collected data were indexed,
integrated and scaled using iMosflm (Battye et al., 2011) and SCALA
(Evans, 2006) from the CCP4 suite (Potterton et al., 2003; Winn et al.,
2011). Molecular replacement was performed by Phaser (McCoy et
al., 2007) using a monomer of E. coli FabG as the search model (PDB
entry 1i01; Price et al., 2001).
3. Results and discussion
Recombinant ypFabG protein was solubly overexpressed in E. coli
at levels of 50 mg per litre of culture. Purification by Ni2+-affinity
chromatography (as described in x2) resulted in greater than 95%
purity, and subsequent purification by size-exclusion chromatography
(Fig. 1) yielded a highly pure, monodisperse protein of approximately
100 kDa, indicative of a tetramer. Initial crystallization conditions
were obtained by screening against the commercial kits Crystal
Screen, Crystal Screen 2, PEG/Ion and PEG/Ion 2. Preliminary
crystals, obtained in condition No. 3 of Crystal Screen (400 mM
ammonium phosphate monobasic), were optimized around salt/
glycerol mixtures as described in x2.3 (Fig. 2). Crystals appearing
after 2 d were flash-cooled in liquid nitrogen on day 12 and X-ray
diffraction data were collected on the MX2 microcrystallography
beamline at the Australian Synchrotron (Fig. 3). Images were
indexed, integrated and scaled to a resolution of 2.30 A˚ (full data-
collection statistics are listed in Table 1). The crystal was ortho-
rhombic with P212121 symmetry, with unit-cell parameters a = 68.22,
b = 98.68, c = 169.84 A˚. Four ypFabG molecules were expected in the
asymmetric unit, giving a Matthews coefficient (VM) of 2.60 A˚
3 Da1
and a solvent content of 52.78% (Kantardjieff & Rupp, 2003;
Matthews, 1968). This was confirmed by the location of a tetramer in
the asymmetric unit by molecular replacement. Following iterative
cycles of model building with WinCoot (Emsley et al., 2010) and
structure refinement with REFMAC5 (Murshudov et al., 2011), the R
and Rfree values were 0.26060 and 0.28938, respectively. The structure
will be fully refined, with a detailed structural and functional analysis
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Figure 2
ypFabG crystals at day 7. (a) Crystals obtained using Hampton Research Crystal
Screen condition No. 3 (400 mM ammonium phosphate monobasic) and (b)
optimized crystal obtained using 300 mM ammonium phosphate monobasic and
30%(w/v) glycerol.
Figure 3
A diffraction pattern of the ypFabG data set collected at the Australian
Synchrotron after 180 of data collection.
Table 1
Data-collection and processing statistics.
Values in parentheses are for the outermost resolution shell.
Crystal system Orthorhombic
Space group P212121
Unit-cell parameters (A˚) a = 68.22, b = 98.68, c = 169.84
Wavelength (A˚) 0.9537
Oscillation angle per frame () 0.5
Exposure time per frame (s) 1.0
Resolution (A˚) 34.11–2.30 (2.37–2.30)
Total reflections 319791 (24239)
Unique reflections 50945 (4329)
Mean I/(I) 11.8 (3.5)






Solvent content (%) 52.78









i IiðhklÞ, where Ii(hkl) is the intensity of
an individual measurement of the reflection with Miller indices hkl and hI(hkl)i is the
mean intensity of that reflection.
P
hkl is the sum over all reflections and
P
i is the sum
over i measurements of reflection hkl. Calculated for I > 3(I).
to be published in a separate paper. Structural analysis of ypFabG will
provide new insights into the biochemical properties of ypFabG and
of FabG proteins of other species from the Yersinia genus.
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